COVID-19 infection does not appear to significantly raise the risk of developing celiac disease. That is the conclusion of a new systematic review and meta-analysis published in Minerva Medica on August 3, 2026, which pooled data from more than 10 million people across four studies to answer a question that has hung over the celiac community since the pandemic began.
For celiac families, this is the kind of result worth sitting with for a moment. Since 2020, a genuine worry has circulated: that COVID-19 might push genetically predisposed people — a sibling, a parent, an undiagnosed child — across the threshold into celiac disease. This study offers the most comprehensive answer yet, and for now, that answer is reassuring.
What This Means for You
The core finding is straightforward: people who had COVID-19 did not develop celiac disease at meaningfully higher rates than people who never had COVID-19. When researchers combined data from over 3.4 million people who had been infected and more than 7 million who had not, the difference in celiac diagnoses between the two groups was not statistically significant.
This matters to me as a celiac parent. My son’s first-degree relatives — the people sharing his household, his genetics, his daily gluten-free life — are already at elevated lifetime risk for celiac disease simply by relationship. The prospect that a COVID-19 infection might accelerate that risk was a real concern. The current evidence says it probably does not, and that is worth knowing.
A few caveats belong here. The pooled risk ratio was 1.25, which sounds like a 25% increase — but the statistical range around that estimate was wide enough to include no increase at all. When the researchers ran a secondary analysis to test the stability of their results, the estimated increase shrank further, to just 10%, and again fell short of statistical significance. The honest read is: there may be a small trend, but it is not proven, and it may be noise.
Routine screening for celiac disease in first-degree relatives remains the right call regardless of COVID history. This study does not change that guidance.
Key Takeaways
- COVID-19 infection does not appear to significantly increase the risk of developing celiac disease.
- The analysis covered more than 10 million people — one of the largest evidence pools on this question to date.
- A modest upward trend existed in the raw data, but it did not reach statistical significance in either the main analysis or the sensitivity check.
- First-degree relatives of celiac patients should continue periodic screening as recommended by their gastroenterologist.
- This research area is still developing — only four studies were available for pooling, and further research is needed.
The Science
Want to understand how this research actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
What Kind of Study Is This?
This is a systematic review and meta-analysis — one of the highest-quality evidence types in medicine. Rather than running a new experiment, the researchers searched multiple databases (MEDLINE/PubMed, the Cochrane Library, and ClinicalTrials.gov) using a standardized protocol to find every published study examining celiac disease rates after COVID-19 infection. They then pooled those studies mathematically to get a larger, more reliable estimate than any single study could provide.
The team — Christina Mastori-Kourmpani, Theodosios D. Filippatos, and Aris P. Agouridis, based in Athens and Crete — pre-registered their methodology (PROSPERO ID: CRD420251174742) before running the analysis. Pre-registration means the research plan is publicly logged in advance, which prevents researchers from adjusting their approach after seeing the data — a key safeguard against bias.
Breaking Down the Numbers
Four qualifying studies were available, all conducted between 2023 and 2024. Combined, they covered:
- 3,465,996 people who had COVID-19 (the “exposed” group)
- 7,044,493 people who had not had COVID-19 (the “non-exposed” group)
The main result was a risk ratio (RR) of 1.25, with a 95% confidence interval (CI) of 0.94 to 1.66 and a p-value of 0.12.
Here is what those terms mean:
A risk ratio compares how often an outcome occurs in one group versus another. An RR of 1.0 means identical risk. An RR of 1.25 suggests 25% more celiac diagnoses in the COVID-19 group — but only if you read the number in isolation.
The confidence interval is where the story becomes more nuanced. A 95% CI of 0.94 to 1.66 means the true risk ratio is statistically plausible anywhere in that range. Because the lower bound (0.94) falls below 1.0, the data are compatible with no increase at all. When a confidence interval crosses 1.0, the result is not statistically significant.
The p-value of 0.12 confirms this: it exceeds the conventional significance threshold of 0.05, meaning researchers cannot rule out that the trend is due to chance.
There was also substantial heterogeneity among the four studies — an I² value of 87%, indicating that the individual studies disagreed considerably with each other. High heterogeneity is a yellow flag: it suggests pooling the studies may be combining apples and oranges.
The Sensitivity Analysis Tells an Interesting Story
To test stability, the researchers ran a leave-one-out sensitivity analysis — they removed one study at a time and re-calculated the result. When they did, the risk ratio dropped to 1.10 (95% CI [1.00, 1.22], P=0.06) and heterogeneity collapsed to zero (I²=0%). The studies suddenly agreed with each other almost perfectly. The result still fell just outside conventional significance, but the picture became far more consistent.
This pattern suggests one outlying study was responsible for most of the disagreement and most of the apparent elevation in risk. Remove it, and the remaining evidence consistently points toward little to no meaningful link between COVID-19 and celiac disease incidence.
Why Were Researchers Asking This Question?
COVID-19 has been associated with increased rates of several auto-inflammatory and autoimmune conditions — diseases where the immune system becomes dysregulated and attacks the body’s own tissue. Celiac disease is an autoimmune disorder triggered by gluten, in which immune activity damages the small intestinal villi (the finger-like projections lining the gut that absorb nutrients).
The hypothesis was that SARS-CoV-2, the virus behind COVID-19, might disrupt gut immunity or immune regulation in ways that accelerate celiac onset in genetically susceptible people. This study’s evidence does not support that hypothesis at a population level — though the researchers acknowledge the available data remain limited, and continued study is warranted.
The Bigger Picture
The COVID-19 and celiac disease intersection has drawn sustained research attention. We previously examined a different dimension of this overlap in our coverage of psychological distress in celiac patients during the pandemic — the anxiety and isolation that came from managing an immune-related dietary condition during a respiratory pandemic. This new study addresses a separate question: whether infection itself changes the autoimmune landscape.
For now, the answer appears to be: not significantly. That does not mean COVID-19 has no relationship with immune health — the field continues to study long COVID and its effects on inflammation broadly. But for celiac families specifically worried about infection tipping the scales toward a new diagnosis, this study is the most reassuring evidence available.
Related Coverage
References
Mastori-Kourmpani C, Filippatos TD, Agouridis AP. Celiac disease incidence after COVID-19 infection. Minerva Medica. Published online August 3, 2026. doi:10.23736/S0026-4806.26.09921-0